Vaishali Pharma Ltd Stock Price Today (NSE: VAISHALI)
Fundamental Score
Vaishali Pharma Ltd Share Price Live NSE/BSE & Institutional Fundamental Analysis
Vaishali Pharma Ltd share price today is ₹7.68, up +0.00% on NSE/BSE as of 20 February 2026. Vaishali Pharma Ltd (VAISHALI) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹94.01 (Cr). The 52-week high for VAISHALI share price is ₹N/A and the 52-week low is ₹N/A. The company has a Return on Equity (ROE) of 1.52% and a debt-to-equity ratio of 0.23.
Vaishali Pharma Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Vaishali Pharma Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Vaishali Pharma Share Price: A Conservative Value Investor's Perspective
The pharmaceutical industry, while offering potential for high returns due to continuous innovation and healthcare demand, also carries significant regulatory and research & development risks. Today's analysis focuses on the Vaishali Pharma share price, currently trading at ₹7.91. A conservative value investor prioritizes capital safety, demanding a thorough examination of fundamentals before considering any investment. This analysis, part of an 80-parameter fundamental audit verified by Sweta Mishra, aims to provide an objective assessment of Vaishali Pharma's financial standing, with an emphasis on risk mitigation.
One crucial metric for evaluating a company's efficiency is Return on Capital Employed (ROCE). Vaishali Pharma currently exhibits a ROCE of 4.93%. This relatively low ROCE raises concerns about the company's ability to generate profits from its invested capital. From a value investing perspective, a low ROCE can indicate a weak competitive advantage, or "moat." Unlike firms such as
Mankind Pharma Ltd, where experienced leadership has fostered successful product portfolios, a lower ROCE suggests that Vaishali Pharma might face challenges in effectively deploying capital and generating consistent returns for shareholders.Further investigation into sector peers is warranted. Considering companies like Smruthi Organics Ltd and Balaxi Pharmaceuticals Ltd can provide context on industry-specific benchmarks. However, each company possesses unique circumstances, and direct comparison requires careful consideration of factors like product mix, market access, and regulatory compliance.
Ultimately, the low ROCE observed impacts the perceived safety of capital. A higher ROCE would indicate a stronger ability to reinvest earnings and grow the business. A deeper dive into the company's financial statements, including cash flow generation, debt levels, and management commentary, is essential to form a more complete understanding. This analysis presents observations based on available data and is intended for informational purposes only. No investment recommendations are expressed.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Vaishali Pharma Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of VAISHALI across key market metrics for learning purposes.
Positive Indicators
5 factors identified
Strong Revenue Growth (60.89%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Excellent EPS Growth (93.18% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (93.79% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.23)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
7 factors identified
Below-Average Return on Equity (1.52%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (4.93%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Profit Decline Concern (-40.10%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Weak Interest Coverage (0.83x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Negative Free Cash Flow (₹-14.52 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Low Promoter Commitment (26.32%)
Observation: Reduced promoter stake may indicate limited confidence.
Analysis: Low promoter holding may raise questions about management commitment.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Vaishali Pharma Ltd Financial Statements
Comprehensive financial data for Vaishali Pharma Ltd including income statement, balance sheet and cash flow
About VAISHALI (Vaishali Pharma Ltd)
Vaishali Pharma Ltd (VAISHALI) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Pharmaceuticals sector with a current market capitalisation of ₹94.01 (Cr). Vaishali Pharma Ltd has delivered a Return on Equity (ROE) of 1.52% and a ROCE of 4.93%. The debt-to-equity ratio stands at 0.23, reflecting the company's capital structure. Investors tracking VAISHALI share price can monitor key metrics including P/E ratio, promoter holding of 26.32%, and quarterly earnings growth.
Company Details
Key Leadership
Latest News
VAISHALI Share Price: Frequently Asked Questions
What is the current share price of Vaishali Pharma Ltd (VAISHALI)?
As of 20 Feb 2026, 06:26 am IST, Vaishali Pharma Ltd share price is ₹7.68. The VAISHALI stock has a market capitalisation of ₹94.01 (Cr) on NSE/BSE.
Is VAISHALI share price Overvalued or Undervalued?
VAISHALI share price is currently trading at a P/E ratio of 0.00x, compared to the industry average of 31.77x. Based on this relative valuation, the Vaishali Pharma Ltd stock appears to be Fairly Valued against its sector peers.
What is the 52-week high and low of VAISHALI share price?
The 52-week high of VAISHALI share price is ₹N/A and the 52-week low is ₹N/A.
What factors affect the Vaishali Pharma Ltd share price?
Key factors influencing VAISHALI share price include quarterly earnings growth (Sales Growth: 60.89%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Vaishali Pharma Ltd a good stock for long-term investment?
Vaishali Pharma Ltd shows a 5-year Profit Growth of 93.79% and an ROE of 1.52%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.23 before investing in VAISHALI shares.
How does Vaishali Pharma Ltd compare with its industry peers?
Vaishali Pharma Ltd competes with major peers in the Pharmaceuticals. Investors should compare VAISHALI share price P/E of 0.00x and ROE of 1.52% against the industry averages to determine competitive standing.
What is the P/E ratio of VAISHALI and what does it mean?
VAISHALI share price has a P/E ratio of N/Ax compared to the industry average of 31.77x. Investors pay ₹N/A for every ₹1 of annual earnings.
How is VAISHALI performing according to Bull Run's analysis?
VAISHALI has a Bull Run fundamental score of 30.2/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does VAISHALI belong to?
VAISHALI operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Vaishali Pharma Ltd share price.
What is Return on Equity (ROE) and why is it important for VAISHALI?
VAISHALI has an ROE of 1.52%, which suggests challenges in generating returns from shareholders equity. ROE measures how efficiently Vaishali Pharma Ltd generates profits from shareholders capital.
How is VAISHALI debt-to-equity ratio and what does it indicate?
VAISHALI has a debt-to-equity ratio of 0.23, which indicates conservative financing with low financial risk.
What is VAISHALI dividend yield and is it a good dividend stock?
VAISHALI offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Vaishali Pharma Ltd shares.
How has VAISHALI share price grown over the past 5 years?
VAISHALI has achieved 5-year growth rates of: Sales Growth 10.51%, Profit Growth 93.79%, and EPS Growth 93.18%.
What is the promoter holding in VAISHALI and why does it matter?
Promoters hold 26.32% of VAISHALI shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Vaishali Pharma Ltd.
What is VAISHALI market capitalisation category?
VAISHALI has a market capitalisation of ₹94 crores, placing it in the Small-cap category.
How volatile is VAISHALI stock?
VAISHALI has a beta of N/A. A beta > 1 suggests the Vaishali Pharma Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is VAISHALI operating profit margin trend?
VAISHALI has a 5-year average Operating Profit Margin (OPM) of 5.50%, indicating the company's operational efficiency.
How is VAISHALI quarterly performance?
Recent quarterly performance shows Vaishali Pharma Ltd YoY Sales Growth of 60.89% and YoY Profit Growth of -40.10%.
What is the institutional holding pattern in VAISHALI?
VAISHALI has FII holding of 0.00% and DII holding of 0.00%. Significant institutional holding often suggests professional confidence in the Vaishali Pharma Ltd stock.